(Adds details on trial in paragraphs 2 and 3, background in paragraph 4)
Sept 7 (Reuters) - Alnylam Pharmaceuticals said on Thursday its experimental therapy for high blood pressure met the main goal in a mid-stage study.
The therapy, zilebesiran, helped reduce the average systolic blood pressure - the pressure in arteries when the heart beats - over a 24 hour period after three months of treatment compared to placebo.
There was also a significant improvement in blood pressure after six months compared to placebo, one of the secondary goals for the study, the company said.
High blood pressure, or hypertension, is a very common chronic illness globally, and has a number of generic drugs for the treatment. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
